Acadian Asset Management LLC grew its position in shares of Ophthotech Corp (NASDAQ:OPHT) by 4.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,216,555 shares of the biopharmaceutical company’s stock after purchasing an additional 52,287 shares during the period. Acadian Asset Management LLC owned 3.36% of Ophthotech worth $2,872,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. acquired a new stake in shares of Ophthotech during the 2nd quarter worth about $100,000. Northern Trust Corp boosted its stake in shares of Ophthotech by 40.2% during the 1st quarter. Northern Trust Corp now owns 74,452 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 21,330 shares during the last quarter. Spark Investment Management LLC boosted its stake in shares of Ophthotech by 25.1% during the 2nd quarter. Spark Investment Management LLC now owns 536,300 shares of the biopharmaceutical company’s stock worth $1,464,000 after purchasing an additional 107,600 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Ophthotech by 202.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 563,271 shares of the biopharmaceutical company’s stock worth $1,543,000 after purchasing an additional 377,267 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Ophthotech by 80.6% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 739,987 shares of the biopharmaceutical company’s stock worth $2,020,000 after purchasing an additional 330,226 shares during the last quarter. 56.42% of the stock is currently owned by institutional investors.
Several research analysts have recently weighed in on the stock. ValuEngine upgraded shares of Ophthotech from a “sell” rating to a “hold” rating in a report on Tuesday, October 2nd. Chardan Capital reiterated a “hold” rating and set a $4.00 price objective on shares of Ophthotech in a report on Thursday, August 2nd. One analyst has rated the stock with a sell rating and three have assigned a hold rating to the company. The company presently has an average rating of “Hold” and an average price target of $3.50.
Shares of OPHT stock opened at $2.22 on Friday. The stock has a market cap of $94.09 million, a PE ratio of 0.70 and a beta of 1.13. Ophthotech Corp has a 1-year low of $2.16 and a 1-year high of $4.50.
Ophthotech (NASDAQ:OPHT) last announced its quarterly earnings data on Wednesday, October 31st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.02. As a group, research analysts anticipate that Ophthotech Corp will post -1.55 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Acadian Asset Management LLC Raises Position in Ophthotech Corp (OPHT)” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/11/10/acadian-asset-management-llc-raises-position-in-ophthotech-corp-opht.html.
Ophthotech Company Profile
Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula.
Featured Story: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.